Pfizer: starts new Duchenne's drug trial

(CercleFinance.com) - Pfizer has launched an early-stage clinical study to test a gene therapy in boys with Duchenne muscular dystrophy, a serious genetic disease characterized by muscle degeneration, the US drugmaker said on Thursday.


At the end of March, a first boy received an infusion of the mini-dystrophin gene, administered under the supervision of investigators at Duke University Medical Center, the company said.

Patient enrollment is expected to continue at up to four clinical research sites in the United States.

Early data from the trial is due in the first half of 2019, once all patients have been assessed for one full year post-treatment.



Copyright (c) 2018 CercleFinance.com. All rights reserved.